227 related articles for article (PubMed ID: 28019723)
1. Therapeutical potential of deregulated lysine methyltransferase SMYD3 as a safe target for novel anticancer agents.
Rajajeyabalachandran G; Kumar S; Murugesan T; Ekambaram S; Padmavathy R; Jegatheesan SK; Mullangi R; Rajagopal S
Expert Opin Ther Targets; 2017 Feb; 21(2):145-157. PubMed ID: 28019723
[TBL] [Abstract][Full Text] [Related]
2. Smyd3-associated regulatory pathways in cancer.
Giakountis A; Moulos P; Sarris ME; Hatzis P; Talianidis I
Semin Cancer Biol; 2017 Feb; 42():70-80. PubMed ID: 27554136
[TBL] [Abstract][Full Text] [Related]
3. Lysine methylation in cancer: SMYD3-MAP3K2 teaches us new lessons in the Ras-ERK pathway.
Colón-Bolea P; Crespo P
Bioessays; 2014 Dec; 36(12):1162-9. PubMed ID: 25382779
[TBL] [Abstract][Full Text] [Related]
4. SMYD3: a regulator of epigenetic and signaling pathways in cancer.
Bernard BJ; Nigam N; Burkitt K; Saloura V
Clin Epigenetics; 2021 Feb; 13(1):45. PubMed ID: 33637115
[TBL] [Abstract][Full Text] [Related]
5. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells.
Hamamoto R; Furukawa Y; Morita M; Iimura Y; Silva FP; Li M; Yagyu R; Nakamura Y
Nat Cell Biol; 2004 Aug; 6(8):731-40. PubMed ID: 15235609
[TBL] [Abstract][Full Text] [Related]
6. SMYD3: An Oncogenic Driver Targeting Epigenetic Regulation and Signaling Pathways.
Bottino C; Peserico A; Simone C; Caretti G
Cancers (Basel); 2020 Jan; 12(1):. PubMed ID: 31935919
[TBL] [Abstract][Full Text] [Related]
7. Unveiling the Biochemistry of the Epigenetic Regulator SMYD3.
Fabini E; Talibov VO; Mihalic F; Naldi M; Bartolini M; Bertucci C; Del Rio A; Danielson UH
Biochemistry; 2019 Sep; 58(35):3634-3645. PubMed ID: 31389685
[TBL] [Abstract][Full Text] [Related]
8. The telomerase reverse transcriptase (hTERT) gene is a direct target of the histone methyltransferase SMYD3.
Liu C; Fang X; Ge Z; Jalink M; Kyo S; Björkholm M; Gruber A; Sjöberg J; Xu D
Cancer Res; 2007 Mar; 67(6):2626-31. PubMed ID: 17363582
[TBL] [Abstract][Full Text] [Related]
9. SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer.
Mazur PK; Reynoird N; Khatri P; Jansen PW; Wilkinson AW; Liu S; Barbash O; Van Aller GS; Huddleston M; Dhanak D; Tummino PJ; Kruger RG; Garcia BA; Butte AJ; Vermeulen M; Sage J; Gozani O
Nature; 2014 Jun; 510(7504):283-7. PubMed ID: 24847881
[TBL] [Abstract][Full Text] [Related]
10. Structure-Based Design of a Novel SMYD3 Inhibitor that Bridges the SAM-and MEKK2-Binding Pockets.
Van Aller GS; Graves AP; Elkins PA; Bonnette WG; McDevitt PJ; Zappacosta F; Annan RS; Dean TW; Su DS; Carpenter CL; Mohammad HP; Kruger RG
Structure; 2016 May; 24(5):774-781. PubMed ID: 27066749
[TBL] [Abstract][Full Text] [Related]
11. SMYD3 contributes to a more aggressive phenotype of prostate cancer and targets Cyclin D2 through H4K20me3.
Vieira FQ; Costa-Pinheiro P; Almeida-Rios D; Graça I; Monteiro-Reis S; Simões-Sousa S; Carneiro I; Sousa EJ; Godinho MI; Baltazar F; Henrique R; Jerónimo C
Oncotarget; 2015 May; 6(15):13644-57. PubMed ID: 25980436
[TBL] [Abstract][Full Text] [Related]
12. SET and MYND domain containing protein 3 in cancer.
Huang L; Xu AM
Am J Transl Res; 2017; 9(1):1-14. PubMed ID: 28123630
[TBL] [Abstract][Full Text] [Related]
13. Histone lysine methyltransferase SMYD3 promotes oral squamous cell carcinoma tumorigenesis via H3K4me3-mediated HMGA2 transcription.
Yang Z; Liu F; Li Z; Liu N; Yao X; Zhou Y; Zhang L; Jiang P; Liu H; Kong L; Lang C; Xu X; Jia J; Nakajima T; Gu W; Zheng L; Zhang Z
Clin Epigenetics; 2023 May; 15(1):92. PubMed ID: 37237385
[TBL] [Abstract][Full Text] [Related]
14. Histone-modifier gene expression profiles are associated with pathological and clinical outcomes in human breast cancer.
Patani N; Jiang WG; Newbold RF; Mokbel K
Anticancer Res; 2011 Dec; 31(12):4115-25. PubMed ID: 22199269
[TBL] [Abstract][Full Text] [Related]
15. The SMYD3-MAP3K2 signaling axis promotes tumor aggressiveness and metastasis in prostate cancer.
Ikram S; Rege A; Negesse MY; Casanova AG; Reynoird N; Green EM
Sci Adv; 2023 Nov; 9(46):eadi5921. PubMed ID: 37976356
[TBL] [Abstract][Full Text] [Related]
16. Structural Basis for Substrate Preference of SMYD3, a SET Domain-containing Protein Lysine Methyltransferase.
Fu W; Liu N; Qiao Q; Wang M; Min J; Zhu B; Xu RM; Yang N
J Biol Chem; 2016 Apr; 291(17):9173-80. PubMed ID: 26929412
[TBL] [Abstract][Full Text] [Related]
17. Novobiocin decreases SMYD3 expression and inhibits the migration of MDA-MB-231 human breast cancer cells.
Luo XG; Zou JN; Wang SZ; Zhang TC; Xi T
IUBMB Life; 2010 Mar; 62(3):194-9. PubMed ID: 20039369
[TBL] [Abstract][Full Text] [Related]
18. The lysine 831 of vascular endothelial growth factor receptor 1 is a novel target of methylation by SMYD3.
Kunizaki M; Hamamoto R; Silva FP; Yamaguchi K; Nagayasu T; Shibuya M; Nakamura Y; Furukawa Y
Cancer Res; 2007 Nov; 67(22):10759-65. PubMed ID: 18006819
[TBL] [Abstract][Full Text] [Related]
19. Cooperation between SMYD3 and PC4 drives a distinct transcriptional program in cancer cells.
Kim JM; Kim K; Schmidt T; Punj V; Tucker H; Rice JC; Ulmer TS; An W
Nucleic Acids Res; 2015 Oct; 43(18):8868-83. PubMed ID: 26350217
[TBL] [Abstract][Full Text] [Related]
20. Smyd3 open & closed lock mechanism for substrate recruitment: The hinge motion of C-terminal domain inferred from μ-second molecular dynamics simulations.
Chandramouli B; Silvestri V; Scarno M; Ottini L; Chillemi G
Biochim Biophys Acta; 2016 Jul; 1860(7):1466-74. PubMed ID: 27085704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
